Airway Remodeling Factors During Early-Life Rhinovirus Infection and the Effect of Premature Birth

Xilei XuChen¹, Jered Weinstock¹, Maria Arroyo¹, Kyle Salka¹, Elizabeth Chorvinsky¹, Karima Abutaleb¹, Hector Aguilar¹, Ryan Kahanowitch¹, Carlos E. Rodriguez-Martinez²,³, Geovanny F. Perez⁴, María J. Gutierrez⁵ and Gustavo Nino*¹

¹ Division of Pediatric Pulmonary and Sleep Medicine, Children's National Hospital, George Washington University, Washington, DC, United States, ² Department of Pediatric Pulmonology and Pediatric Critical Care Medicine, School of Medicine, Universidad El Bosque, Bogota, Colombia, ³ Department of Pediatric Pulmonology and Pediatric Critical Care Medicine, School of Medicine, Universidad Nacional de Colombia, Bogota, Colombia, ⁴ Division of Pediatric Pulmonology, Oishei Children’s Hospital, University at Buffalo, Buffalo, NY, United States, ⁵ Division of Pediatric Allergy and Immunology, Johns Hopkins University, Baltimore, MD, United States

Background: Early rhinovirus (RV) infection is a strong risk factor for asthma development. Airway remodeling factors play a key role in the progression of the asthmatic condition. We hypothesized that RV infection in young children elicits the secretion of growth factors implicated in airway remodeling and asthma progression.

Methods: We examined the nasal airway production of remodeling factors in children (≤2 years old) hospitalized due to PCR-confirmed RV infection. Airway remodeling proteins included: MMP-1, MMP-2, MMP-7, MMP-9, MMP-10, TIMP-1, TIMP-2, EGF, Angiopoietin-2, G-CSF, BMP-9, Endoglin, Endothelin-1, Leptin, FGF-1, Follistatin, HGF, HB-EGF, PLGF, VEGF-A, VEGF-C, VEGF-D, FGF-2, TGF-β1, TGF-β2, TGF-β3, PDGF AA, PDGF BB, SPARC, Periostin, OPN, and TGF-α.

Results: A total of 43 young children comprising RV cases (n = 26) and uninfected controls (n = 17) were included. Early RV infection was linked to (1) enhanced production of several remodeling factors (e.g., HGF, TGFα), (2) lower MMP-9/TIMP-2 and MMP-2/TIMP-2 ratios, and (3) increased MMP-10/TIMP-1 ratios. We also found that relative to term infants, severely premature children had reduced MMP-9/TIMP-2 ratios at baseline.

Conclusion: RV infection in young children elicits the airway secretion of growth factors implicated in angiogenesis, fibrosis, and extracellular matrix deposition. Our results highlight the potential of investigating virus-induced airway remodeling growth factors during early infancy to monitor and potentially prevent chronic progression of respiratory disorders in all ages.

Keywords: rhinovirus (RV), airway remodeling, prematurity, infancy, growth factor
INTRODUCTION

Human rhinovirus (RV) has been identified as the most common cause of wheezing illnesses and asthma exacerbations in all ages (1). Moreover, RV-induced wheezing illnesses during the first 2–3 years of life are considered the strongest risk factor (10 times increased odds) for the development of asthma beyond childhood (2). This RV-related risk is even higher in individuals with genetic predisposition (e.g., variants at the 17q21 locus) (3) and in those with early life aeroallergen sensitization (4). While most research has focused on how RV contributes to the initiation and progression of allergic inflammation (4), there is evidence that RV may directly induce remodeling factors that promote chronic changes in the airways (5). Airway remodeling is a feature of several chronic airway diseases like asthma and encompasses permanent structural changes including subepithelial thickening, extracellular matrix deposition or fibrosis, and an increase in airway smooth muscle mass (6–8). These airway remodeling changes have been described in young children with airflow limitation even before any diagnosis of asthma (9, 10). Nonetheless, whether RV infections induce the production of remodeling factors in the airways of young children remains to be determined.

Prior studies have shown that RV can upregulate in-vitro remodeling factors in airway epithelial cells including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and specific matrix metalloproteinases (MMP) (11–14). However, the specific remodeling factors produced in the airways of young children with naturally occurring RV infections are presently unknown. Filling this gap can be critically important as it may lead to the identification of novel targetable molecular pathways that mediate chronic progression of RV-induced wheezing illnesses during childhood. This new knowledge would be particularly impactful for children born severely premature as they are highly susceptible to develop severe and recurrent RV infections as well as other virus-induced wheezing illnesses during infancy and beyond childhood (15–20).

The goal of this study was to define for the first time the specific airway remodeling signatures induced by RV during early life. For this purpose, we determined protein levels of 32 remodeling factors in the nasal secretions of young children (≤2 years old) hospitalized with severe RV infections and in uninfected controls. Our central hypothesis was that RV infection in young children elicits the airway secretion of growth factors implicated in angiogenesis, fibrosis, and extracellular matrix deposition. Additional analyses were conducted to identify the effect of severe prematurity in the RV-induced airway remodeling signatures in young children.

METHODS

Study Subjects

Nasal airway secretions were collected in patients ≤2 years old of age with PCR-confirmed RV infection. All subjects were enrolled during the hospital admission for RV infection. We included age-matched controls without viral respiratory infection (negative viral PCR) recruited during non-respiratory hospitalizations or outpatient/emergency department visits. Baseline characteristics were obtained by reviewing electronic medical records (EMR) and are presented in Table 1. Our sample was obtained while they were undergoing diagnostic nasal lavage (respiratory virus detection by PCR) at Children’s National Hospital. RV positive (RV-infected group) or negative virus status (control group) was confirmed by a viral multiplex PCR panel for 12 targets (RV, RSV A, RSV B, HMPV, parainfluenza 1–3, influenza A and B, H1N1, H1N3, Adenovirus) used for clinical purposes (Luminex, TX, USA). Mixed viral infections were not included in the RV positive group. For the purpose of the study, severe prematurity was defined by a gestational age (GA) of ≤32 weeks. The study protocol (Pro00003441) was approved by the Institutional Review Board (IRB) of Children’s National Hospital, Washington D.C.

Nasal Washing Collection and Cytokine Measurements

We used a standard nasal lavage technique consisting of gently washing the nasal cavity with 3–4 mL sterile normal saline as previously described (19). All samples were obtained with the same protocol to minimize variable recovery during nasal aspirate collection. Nasal washings were analyzed for protein levels of 32 growth factors implicated in remodeling and angiogenesis using a commercially available multiplex magnetic bead immunoassay (Millipore, MA, USA) according to the manufacturers’ instructions and with provided standards and quality controls. Protein levels below the immunoassay’s limit of detection (LOD) were assigned the LOD provided in the assay. The following analytes were included: matrix metalloproteinases (MMP-1, MMP-2, MMP-7, MMP-9, and MMP-10), Tissue inhibitor of metalloproteinases (TIMP-1 and TIMP-2), Epidermal growth factor (EGF), Angiopoietin-2, Granulocyte colony-stimulating factor (G-CSF), Bone morphogenic protein-9 (BMP-9), Endoglin, Endothelin-1, Leptin, Fibroblast growth factors (FGF-1 and FGF-2), Follistatin, Hepatic growth factor (HGF), Heparin-binding EGF-like growth factor (HB-EGF), Placental growth factor (PLGF), vascular endothelial growth factors (VEGF-A, VEGF-C, VEGF-D), transforming growth factors (TGF-α, TGF-β1, TGF-β2, and TGF-β3), Platelet-derived growth factors (PDGF-AA and PDGF-BB), Secreted protein acidic and rich in cysteine (SPARC), Periostin and Osteopontin (OPN).

Statistical Analysis

Differences between groups on continuous variables were analyzed using the non-parametric Mann-Whitney U test. Benjamini–Hochberg false discovery rate (FDR) method was used to adjust for multiple comparisons. Associations between categorical variables were analyzed using the X² test. RV-induced changes in MMP/TIMP ratios were adjusted by pertinent covariates using generalized linear regression models. All statistical tests were two-tailed, and the significance level used was p < 0.05. The data were analyzed with the Minitab Statistical Package V.19.1. (Minitab, Inc., State College, PA).
Forty-three children aged ≤2 years of age were included in this study. The total study sample comprised young children hospitalized due to PCR-confirmed RV infections (n = 26) and age-matched uninfected controls (n = 17). To examine the effect of severe prematurity in our main outcome (secretion of airway remodeling factors) we included RV infected and control individuals born full-term or severely premature (≤32 weeks GA). Baseline characteristics of these groups are shown in Table 1.

### RESULTS

**Baseline Characteristics**

Forty-three children aged ≤2 years of age were included in this study. The total study sample comprised young children hospitalized due to PCR-confirmed RV infections (n = 26) and age-matched uninfected controls (n = 17). To examine the effect of severe prematurity in our main outcome (secretion of airway remodeling factors) we included RV infected and control individuals born full-term or severely premature (≤32 weeks GA). Baseline characteristics of these groups are shown in Table 1.

### Airway Remodeling Factors in Young Children During RV Infection

Analysis of individual nasal protein levels of different airway remodeling factors demonstrated that young children hospitalized due to severe RV infection had a significant increase in the production of several soluble growth factors involved in remodeling as compared to uninfected controls. Table 2 shows the complete list of airway remodeling factors according to RV status. We found that during RV infection young children had higher nasal airway responses of TIMP-2, HGF, TGF-α, and MMP-10 (Table 2). Other remodeling factors such as Endoglin, G-CSF, VEGF-D, Leptin, MMP-9, FGF-2, and HB-EGF trended to be increased during RV infection but were not significant after FDR adjustment (Table 2).

To examine the effect of severe prematurity in the production of airway remodeling factors during early life, we first examined the baseline airway production of these molecules in uninfected young children. We found that severely premature children trended to have increased baseline production of several remodeling growth factors (e.g., MMP-2 and TGF-α) but there were no significant differences relative to term infants after FDR adjustment (Table 2). We also contrasted airway remodeling factors in young children born full-term or severely premature during RV infections. We found that relative to full-term children, individuals born severely premature had overall similar RV-induced production of remodeling factors (Table 3). Collectively, these results suggest that RV infection in term and premature young children elicits the airway secretion of specific growth factors implicated in angiogenesis, fibrosis, and extracellular matrix deposition.

### Matrix Metalloproteinase/Tissue Inhibitor Metalloproteinase Ratios in Young Children During RV Infection

Since our individual molecular analyses identified that RV elicits the production of different matrix metalloproteinase (MMP) and tissue inhibitor metalloproteinases (TIMP) in the airways of young children, we next examined MMP/TIMP ratios across our study groups. We focused on specific MMPs (MMP-9, MMP-2, MMP-10) relative to TIMP-1 and TIMP-2 levels, as the ratios of these enzymes have been implicated in the regulation of airway remodeling (21–26) and their individual levels showed significant differences in our study (Table 2). Our results demonstrated that MMP-9/TIMP-2 ratios were significantly decreased in term children after RV infection (Figure 1A). MMP-9/TIMP-2 ratios were low at baseline in severely premature subjects and thus

---

**TABLE 1 | Baseline characteristics of the study subjects.**

|                  | Term Control | Term RV | Severe premature Control | Severe premature RV |
|------------------|--------------|---------|--------------------------|---------------------|
| N (%)            | 6 (14)       | 9 (21)  | 11 (26)                  | 17 (39)             |
| Age (years), mean (SD) | 0.48 (0.46) | 1.22 (0.68) | 0.66 (0.43) | 1.10 (0.60) |
| GA (weeks) mean (SD) | 38.5 (1.05) | 37 (1.93) | 25.8 (1.94) | 25.6 (2.2) |
| Male gender, n (%) | 4 (66)       | 3 (33)  | 10 (90)                  | 11 (65)             |
| Black/African American, n (%) | 2 (33) | 4 (44) | 7 (64) | 11 (66) |

RV, Rhinovirus; GA, Gestational Age; SD, Standard Deviation.

**TABLE 2 | Comparison of airway remodeling factors in young children hospitalized with rhinovirus infection and uninfected controls.**

| Nasal airway protein levels (pg/ml) | Control (n = 17) | Rhinovirus (n = 26) | P-value | Adj. P-value* |
|-------------------------------------|------------------|---------------------|---------|---------------|
| TIMP-2                              | 991.16           | 8996.5              | 0.0001  | 0.003         |
| HGF                                 | 50.74            | 806.82              | 0.001   | 0.017         |
| TGFα                                | 0.81             | 21.71               | 0.001   | 0.011         |
| MMP-10                              | 862.51           | 4,583               | 0.004   | 0.033         |
| Endoglin                            | 15.69            | 26.84               | 0.012   | 0.079         |
| G-CSF                               | 51.88            | 165.62              | 0.015   | 0.082         |
| VEGF-D                              | 5.96             | 4.48                | 0.016   | 0.075         |
| Leptin                              | 86.96            | 74.05               | 0.02    | 0.083         |
| MMP-9                               | 6542             | 13,289              | 0.025   | 0.092         |
| FGF-2                               | 17.78            | 22.78               | 0.031   | 0.102         |
| HB-EGF                              | 4.25             | 14.9                | 0.047   | 0.141         |
| VEGF-A                              | 306.7            | 736.82              | 0.063   | 0.160         |
| FGF-1                               | 6.10             | 8.11                | 0.104   | 0.245         |
| MMP-2                               | 216.03           | 316.19              | 0.14    | 0.272         |
| MMP-7                               | 787.77           | 371.11              | 0.16    | 0.293         |
| MMP-1                               | 21.67            | 11.91               | 0.48    | 0.587         |
| TIMP-1                              | 10,042           | 10787.5             | 0.518   | 0.611         |
| EGF                                 | 47.32            | 100.5               | 0.465   | 0.590         |
| Angiopoietin-2                      | 8.54             | 6.31                | 0.058   | 0.160         |
| BMP-9                               | 0.95             | 1.05                | 0.356   | 0.490         |
| Endothelin-1                        | 4.49             | 3.91                | 0.228   | 0.376         |
| Follistatin                         | 29.74            | 24.31               | 0.214   | 0.372         |
| PLGF                                | 1.95             | 6.11                | 0.249   | 0.391         |
| VEGF-C                              | 19.26            | 54.94               | 0.127   | 0.262         |
| TGFp1                               | 10942.5          | 6,835               | 0.53    | 0.603         |
| TGFp2                               | 15247.5          | 14,299              | 0.339   | 0.486         |
| TGFp3                               | 2,751            | 2,622               | 0.83    | 0.866         |
| PDGF AA                             | 950.84           | 913.41              | 0.786   | 0.837         |
| PDGF BB                             | 6,673            | 6,673               | 0.648   | 0.713         |
| SPARC                               | 0.25             | 0.25                | 0.907   | 0.907         |
| Periostin                           | 0.14             | 0.27                | 0.386   | 0.510         |
| OPN                                 | 327.32           | 267.14              | 0.304   | 0.456         |

*p value adjusted by false discovery rate (FDR). Bold values denote statistical significance (p < 0.05).
TABLE 3 | Comparison of airway remodeling factors at baseline and during RV infection according to severe prematurity status.

| Nasal airway protein levels (pg/ml) | Baseline levels | RV-induced levels |
|-------------------------------------|-----------------|------------------|
|                                     | Term | Premature | P-value | Adj. P-value* | Term | Premature | P-value | Adj. P-value* |
| TIMP-2                              | 487.48 | 1,314 | 0.11 | 0.196 | 9,090 | 8,580 | 0.89 | 0.949 |
| HGF                                 | 34.81 | 144.17 | 0.079 | 0.194 | 899.34 | 806.82 | 0.95 | 0.981 |
| TGFα                                | 1.93 | 14.75 | 0.021 | 0.168 | 21.22 | 16.64 | 0.75 | 1.000 |
| MMP-10                              | 332.96 | 1,437 | 0.11 | 0.220 | 5888.5 | 3,106 | 0.29 | 1.000 |
| Endoglin                            | 14.67 | 19.63 | 0.11 | 0.207 | 17.02 | 32.98 | 0.89 | 0.949 |
| G-CSF                               | 899.34 | 806.82 | 0.95 | 0.981 |
| VEGF-D                              | 4.59 | 6.9 | 0.018 | 0.192 | 15.09 | 12.622 | 0.48 | 0.960 |
| Leptin                              | 76.63 | 98.56 | 0.024 | 0.154 | 10.07 | 7.6 | 0.89 | 0.986 |
| MMP-9                               | 6,386 | 6,542 | 0.62 | 0.763 | 157.09 | 5,107 | 0.29 | 1.000 |
| FGF-2                               | 13.7 | 19 | 0.039 | 0.178 | 23.43 | 20.87 | 0.56 | 1.000 |
| HB-EGF                              | 2.34 | 6.17 | 0.044 | 0.176 | 14 | 15.75 | 0.77 | 0.986 |
| VEGF-A                              | 178.7 | 429.84 | 0.035 | 0.187 | 781.66 | 736.82 | 0.61 | 0.914 |
| FGF-1                               | 4.75 | 7.35 | 0.37 | 0.564 | 5.51 | 9.19 | 0.048 | 1.000 |
| MMP-2                               | 97.54 | 322.8 | 0.009 | 0.144 | 398.88 | 335.46 | 0.21 | 1.000 |
| MMP-7                               | 418.02 | 1.737 | 0.07 | 0.187 | 276.08 | 442.47 | 0.77 | 0.948 |
| MMP-1                               | 16.56 | 21.67 | 1.0 | 1.000 | 13.99 | 11.91 | 0.45 | 1.000 |
| TIMP-1                              | 7,623 | 10,042 | 0.37 | 0.493 | 16,271 | 9,941 | 0.57 | 1.000 |
| EGF                                 | 39.66 | 67.8 | 0.088 | 0.201 | 5.04 | 6.61 | 0.086 | 0.917 |
| Angiopoietin-2                      | 6.61 | 8.84 | 0.063 | 0.202 | 5.04 | 6.61 | 0.086 | 0.917 |
| MMP-9                               | 0.97 | 1.05 | 0.38 | 0.935 |
| Endothelin-1                        | 3.49 | 5.62 | 0.13 | 0.219 | 3.78 | 4.34 | 0.34 | 0.989 |
| Follistatin                          | 22.58 | 30.64 | 0.37 | 0.515 | 26.55 | 21.91 | 0.79 | 0.936 |
| PLGF                                | 1.33 | 3.88 | 0.044 | 0.156 | 5.65 | 7.42 | 1.000 |
| VEGF-C                              | 8.9 | 21.3 | 0.063 | 0.183 | 41.76 | 54.94 | 0.88 | 0.971 |
| TGFp1                               | 15,050 | 6,835 | 0.49 | 0.627 | 6,835 | 841.75 | 0.85 | 0.971 |
| TGFp2                               | 13,197 | 15,580 | 0.73 | 0.865 | 13,197 | 14,299 | 0.55 | 0.978 |
| TGFp3                               | 1,774 | 2,815 | 0.78 | 0.861 | 1,806 | 392.15 | 0.24 | 1.000 |
| PDGF AA                             | 1,034 | 867.69 | 0.95 | 0.981 | 913.41 | 909.71 | 0.53 | 0.998 |
| PDGF BB                             | 100 | 6,61 | 0.086 | 0.202 | 10,000 | 4215.5 | 0.33 | 1.000 |
| SPARC                               | 0.33 | 0.19 | 0.31 | 0.496 | 0.22 | 0.25 | 0.24 | 1.000 |
| Periostin                           | 0.095 | 0.26 | 0.088 | 0.188 | 0.35 | 0.11 | 0.35 | 0.933 |
| OPN                                 | 268.65 | 337.84 | 0.76 | 0.869 | 241.18 | 288 | 0.228 | 1.000 |

*p-value adjusted by false discovery rate (FDR).

were not further decreased during RV infection (Figure 1A). We also identified that RV infection in young children was linked to a decreased MMP-2/TIMP-2 and an increased MMP-10/TIMP-1 ratios. The later RV-induced changes were similar in term and premature children (Figures 1B,C). Multivariate analyses demonstrated that the RV-induced changes in the MMP-9/TIMP-2, MMP-2/TIMP-2, and MMP10/TIMP-1 ratios were independent of age, sex, and race/ethnicity (Table 4). Taken together, these data demonstrate that RV infection elicits significant changes in the enzymatic MMP/TIMP balance in the airways of young children.

**DISCUSSION**

The goal of this study was to define for the first time the specific airway remodeling signatures induced by RV during early life. This is a high-impact Research Topic because RV is the most common cause of wheezing illnesses and early life RV infections confer a significantly increased risk for the development of asthma beyond childhood (2). Our results demonstrate that RV infection in young children elicits the airway secretion of growth factors implicated in angiogenesis, fibrosis, and extracellular matrix deposition. We also found intrinsic differences in the baseline airway remodeling factors between young children born full-term and those born severely premature. Our results highlight the potential of investigating virus-induced airway remodeling growth factors during early infancy to monitor and potentially prevent chronic respiratory disorders in all ages.

There is prior evidence that RV can induce growth factors implicated in healing and remodeling in airway epithelial cells (11–14). In this study, we found that the overall top growth factors induced by RV in young children were transforming...
FIGURE 1 | Nasal airway MMP/TIMP ratios at baseline and during RV infection in young children according to severe prematurity status. Comparison of nasal protein levels of matrix metalloproteinases (MMP) and tissue inhibitor metalloproteinases (TIMP) ratios in non-infected controls (CT) and young children with rhinovirus (RV) infection. (A) MMP9/TIMP2 is increased in CT term relative to RV infection and CT in premature; (B) MMP2/TIMP2 is increased in CT relative to RV in term and premature; (C) MMP10/TIMP1 is increased in RV infection relative to CT in term and premature. Symbols represent *p < 0.05 and **p < 0.01; no other pairwise comparisons were significant. Data presented as boxplots representing 25th–75th percentiles.
growth factor alpha (TGF-α) and hepatic growth factor (HGF) (Table 2). TGF-α binds the epidermal growth factor receptor (EGFR) in the epithelium to exert a myriad of potent effects in the airways including maturation, remodeling and increased mucous production (27). HGF is produced by mesenchymal cells and after binding its receptor in the airway epithelium (c-Met), it induces many protective effects including inhibition of apoptosis and oxidative stress injuries (28) as well as attenuation of airway hyperresponsiveness, inflammation, and remodeling (29). The production of TGF-α and HGF has been described during RV infection in cellular models (30, 31), but to the best of our knowledge, our study is the first to report this in young children during naturally occurring RV infections. It is also important to emphasize that several other remodeling growth factors were increased during RV infections in term and premature infants (Tables 2, 3). These growth factors and other related molecules are likely to collectively form a network of signaling responses to orchestrate healing, repair as well as fibrosis in response to RV in early life. As a result, their collective function, rather than individual effects, is likely to play a significant role not only in acute RV infections but also during subsequent airway responses after recovery.

Along with the effect of RV in multiple airway growth factors, we also found that this virus altered the balance of matrix metalloproteinase (MMP) and tissue inhibitor metalloproteinases (TIMP) enzymes in the airways of young children. This is relevant because the imbalance between MMP/TIMP molecules is considered a major theory to explain the progression of airway remodeling (21–26). MMPs, and their putative inhibitors TIMPs, are the key enzymes responsible for extracellular matrix degradation and thus regulate healing and repair processes as well as the development of fibrotic changes (21–26). The ratios of these molecules have been directly correlated with airway remodeling changes in humans (21–26). Low sputum MMP-9/TIMP2 ratios are associated with airway narrowing in smokers with asthma (22) and MMP-9/TIMP1 ratios correlate inversely with airway wall thickness assessed by CT scanning in asthmatics (23). In our study, we found that RV infection is associated with reduced MMP-9/TIMP2 ratios suggesting that this virus may play a role inducing remodeling changes in early life. Interestingly, severely premature children had low MMP-9/TIMP2 levels at baseline, which might indicate the presence of chronic remodeling changes due to prematurity-related injuries and/or developmental deficits. We also found that RV decreases MMP2/TIMP-2 levels while increasing MMP-10/TIMP-1 ratios. This profile also supports that RV promotes airway remodeling changes in young children. MMP-2 is generally considered protective for the airways (24), however MMP-10 is induced by viral infections (25) and is linked to increased submucosal thickness (26). In summary, our study clearly demonstrated that RV induces an imbalance between MMP/TIMP molecules. However, it is important to emphasize that in early life these changes could be part of the normal airway development and/or repairing responses after virus-induced injuries. Additional studies are needed to understand if RV-induced MMP/TIMP imbalances have any deleterious effects in the progression of respiratory illnesses in young children born at term or severely premature.

In addition to reduced MMP-9/TIMP2 ratios, we have previously shown that severely premature children have increased airway secretion of TH2 and TH17 cytokines during RV infections (19). Our current findings complement this initial observation demonstrating that RV not only elicits an airway pro-inflammatory state but heightens the production of angiogenic and pro-fibrotic factors in severely premature infants. While some RV-induced airway remodeling factors are likely to be protective, some may contribute to increased respiratory morbidity. Defining the clinical relevance of these changes will be important as RV infections are a major cause of health care utilization, hospitalization, and morbidity in premature children (15–20). The later may relate to deficits in lung function such as higher resistance of the respiratory system during early infancy (32, 33). Since airway remodeling contributes to changes in the bronchial wall leading to increased resistance (6–8), it is possible that RV-induced angiogenic and pro-fibrotic factors may be clinically relevant by predisposing infants to severe and recurrent virus-induced wheezing illnesses in early childhood, particularly in those born prematurely. This important possibility needs to be considered in future larger longitudinal studies.

Our study has a number of strengths and some limitations. We were able to investigate multiple remodeling growth factors not previously reported in the literature of RV infection in young children. In that sense, our study successfully provided important novel molecular insights on the potential effects of viruses in the regulation of remodeling responses during early childhood. The main limitations of the present study are the sample size and the cross-sectional nature of the sampling. It is important to emphasize that this is a small
pilot study and our findings need prospective validation and clinical correlation. Indeed, prospective sampling is needed to confirm the increase in remodeling factors once RV infection occurs in early life, and whether this normalizes later or continues well into late childhood. In addition, the study was conducted in a specialized, tertiary referral hospital, which makes it likely that the patients included represent the extreme of the spectrum of severity of infants born premature, thus limiting the generalization of results to other contexts. Another important caveat is that the concentrations of growth factors in the nasal passages do not necessarily reflect those in the lower airway. Our study included only nasal samples as bronchial specimens cannot be readily obtained during acute RV infections in young children. However, in this regard, there is a large body of literature demonstrating nasal and bronchial respiratory epithelial similarities with approximately 91% homology in the expressed genes between the two sites (34). Accordingly, although further studies including bronchial specimens are still needed, nasal sampling is a non-invasive approach to examining virus-induced airway responses in infants and young children (35–37). Because the focus of the study was the quantification of remodeling factors we did not include viral loads, cytokines or clinical data (e.g., nasal lavage cell counts, severity of infection/duration of hospitalization), which are important variables during RV infections in infants. Finally, because EMR information did not provide a complete medical history in all cases, we did not include in the analyses some potentially important factors for RV infection severity such as eczema, socioeconomic status and environmental factors (e.g., smoking and daycare attendance), prematurity-related factors (O2, chronic lung disease, steroids use) and as is the case for other observational epidemiologic studies, residual confounding cannot be excluded, so interpretation of our results needs to be cautious.

In conclusion, our study identified that (1) RV infection in term and premature young children is linked to an enhanced secretion of growth factors implicated in airway remodeling (TIMP-2, HGF, TGF-α, and MMP-10); and (2) severely premature children have reduced nasal airway MMP-9/TIMP-2 ratios at baseline. Further investigating the underlying molecular mechanisms linking early RV infection to airway remodeling could lead to novel biomarkers and targeted interventions to prevent chronic progression of respiratory diseases in children.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article-supplementary material, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Institutional Review Board (IRB) of Children's National Hospital, Washington D.C. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

**AUTHOR CONTRIBUTIONS**

XX-C and GN: study design. XX-C, JW, MA, HA, RK, GP, and GN: data collection. GN, CR-M, JW, MG, and XX-C: analysis. All authors: manuscript drafting, editing, approval.

**FUNDING**

This work was supported by NIH Grant HL145669 and HL141237.

**REFERENCES**

1. Friedlander SL, Busse WW. The role of rhinovirus in asthma exacerbations. *J Allergy Clin Immunol*. (2005) 116:267–73. doi: 10.1016/j.jaci.2005.06.003

2. Jackson DJ, Gagnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. *Am J Respir Crit Care Med*. (2008) 178:667–72. doi: 10.1164/rccm.200802-309OC

3. Calişkan M, Bochkov YA, Kreiner-Moller E, Bønneelykke K, Stein MM, Du G, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. *N Engl J Med*. (2013) 368:1398–407. doi: 10.1056/NEJMoa1211592

4. Stoner AN, Jones SM. Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence. *J Allergy Clin Immunol*. (2017) 139:501–7. doi: 10.1016/j.jaci.2016.03.049

5. Mela A, Kaochueak P, Brevard D, Croft M. Tumor necrosis factor family member LIGHT acts with IL-1β and TGF-β to promote airway remodeling during rhinovirus infection. *Allergy*. (2018) 73:1415–24. doi: 10.1111/all.13390

6. Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. (2004) 1:176–83. doi: 10.1513/pats.200402-009MS

7. Pepe C, Foley S, Shannon J, Lemiere C, Olivenstein R, Ernst P, et al. Differences in airway remodeling between subjects with severe and moderate asthma. *J Allergy Clin Immunol*. (2005) 116:544–9. doi: 10.1016/j.jaci.2005.06.011

8. Kaminska M, Foley S, Maghni K, Storness-Bliss C, Coxson H, Ghezzo H, et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. *J Allergy Clin Immunol*. (2009) 124:45–51. doi: 10.1016/j.jaci.2009.03.049

9. Berankova K, Uhlík J, Honkova L, Pohunek P. Structural changes in the bronchial mucosa of young children at risk of developing asthma. *Pediatr Allergy Immunol*. (2014) 25:136–42. doi: 10.1111/pai.12119

10. Saglani S, Payne DN, Zhu J, Wang Z, Nicholson AG, Bush A, et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. *Am J Respir Crit Care Med*. (2007) 176:858–64. doi: 10.1164/rccm.200702-212OC

11. Leigh R, Oyelusi W, Wiesler S, Koetzler R, Zaheer RS, Newton R, et al. Human rhinovirus infection enhances airway epithelial cell production of growth factors involved in airway remodeling. *J Allergy Clin Immunol*. (2008) 121:1238–45. doi: 10.1016/j.jaci.2008.01.067

12. Skvaki CL, Pasuurs S, Volonaki E, Pratsinis H, Spyridaki IS, Gaga M, et al. Rhinovirus-induced basic fibroblast growth factor release mediates airway remodeling features. *Clin Transl Allergy*. (2012) 2:14. doi: 10.1186/2045-7022-2-14

13. Bochkov YA, Hanson KM, Keles S, Brockman-Schneider RA, Jarjour NN, Gern JE. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. *Mucosal Immunol*. (2010) 3:69–80. doi: 10.1038/mi.2009.109
14. Tacoen CE, Wehler S, Holden NS, Newton R, Proud D, Leigh R. Human rhinovirus infection upregulates MMP-9 production in airway epithelial cells via NF-κB. *Am J Respir Cell Mol Biol*. (2010) 43:201–9. doi: 10.1165/rcmb.2009-0216OC

15. Drysdale SB, Alcazar-Paris M, Wilson T, Smith M, Zuckerman M, Broughton S, et al. Rhinovirus infection and healthcare utilisation in prematurely born infants. *Eur Respir J*. (2013) 42:1029–36. doi: 10.1183/09031936.00109012

16. Drysdale SB, Alcazar M, Wilson T, Smith M, Zuckerman M, Lauinger IL, et al. Respiratory outcome of prematurely born infants following human rhinovirus A and C infections. *Eur J Pediatr*. (2014) 173:913–9. doi: 10.1007/s00431-014-2262-1

17. Miller EK, Buga J, Libster R, Shepherd BE, Scalzo PM, Acosta PL, et al. Human rhinoviruses in severe respiratory disease in very low birth weight infants. *Pediatrics*. (2012) 129:60–7. doi: 10.1542/peds.2011-0583

18. Perez GF, Kurdi B, Megalaa R, Pancham K, Huseni S, Isaza N, et al. Phenotypical characterization of human rhinovirus infections in severely premature children. *Pediatr Neonatol*. (2018) 59:244–50. doi: 10.1016/j.pedneo.2017.04.008

19. Perez GF, Pancham K, Huseni S, Jain A, Rodriguez-Martinez CE, Preciado D, et al. Rhinovirus-induced airway cytokines and respiratory morbidity in severely premature children. *Pediatr Allergy Immunol*. (2015) 26:145–52. doi: 10.1111/pai.12346

20. Drysdale SB, Alcazar M, Wilson T, Smith M, Zuckerman M, Hudemakers HM, et al. Functional and genetic predisposition to rhinovirus lower respiratory tract infections in prematurely born infants. *Eur J Pediatr*. (2016) 175:1943–9. doi: 10.1007/s00431-016-2780-0

21. Ohbayashi H, Shimokata K. Matrix metalloproteinase-9 and airway remodeling in asthma. *Curr Drug Targets Inflamm Allergy*. (2005) 4:177–81. doi: 10.2174/1568010053586246

22. Chaudhuri R, McSharry C, Brady J, Grierson C, Messow CM, Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES, et al. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. *Thorax*. (2005) 60:277–81. doi: 10.1136/thx.2004.028936

23. Takahashi Y, Kobayashi T, D’Alessandro-Gabazza CN, Toda M, Fujiwara K, Okano T, et al. Protective role of matrix metalloproteinase-2 in allergic bronchial asthma. *Front Immunol*. (2019) 10:1795. doi: 10.3389/fimmu.2019.01795

24. Hirakawa S, Kojima T, Obata K, Okabayashi T, Yokota S, Nomura K, et al. Marked induction of matrix metalloproteinase-10 by respiratory syncytial virus infection in human nasal epithelial cells. *J Med Virol*. (2013) 85:2141–50. doi: 10.1002/jmv.23718

25. Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES. Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. *J Biol Chem*. (2012) 287:15935–46. doi: 10.1074/jbc.M112.341156

26. Tadaki H, Arakawa H, Mizuno T, Suzuki T, Takeyama K, Mochizuki H, et al. Double-stranded RNA and TGF-α promote MUC5AC induction in respiratory cells. *J Immunol*. (2009) 182:293–300. doi: 10.4049/jimmunol.182.1.293

27. Okada M, Sugita K, Inukai T, Goto K, Kagami K, Kawasaki K, et al. Hepatocyte growth factor protects small airway epithelial cells from apoptosis induced by tumor necrosis factor-alpha or oxidative stress. *Pediatr Res*. (2004) 56:336–44. doi: 10.1203/01.PDR.0000031253.58638.59

28. Ito W, Kamehiro A, Matsumoto K, Hirano A, Ono K, Maruyama H, et al. Hepatocyte growth factor attenuates airway hyperresponsiveness, inflammation, and remodeling. *Am J Respir Cell Mol Biol*. (2005) 32:268–80. doi: 10.1165/rcmb.2004-0058OC

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 XuChen, Weinstock, Arroyo, Salka, Chorvinsky, Abutaleb, Agudial, Kahnawanitch, Rodriguez-Martinez, Perez, Gutierrez and Nino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.